EUVIMEDEUVIMED entdecken
Vergleichsstudie

Effects of Angiotensin Converting Enzyme Inhibitors versus Angiotensin Receptor Blockers on Cognitive Decline: A Retrospective Real-World Database Study

Laith Rhabneh, Raed Ababneh, Abdallah Al-Muhtaseb, Mohammed Aloqaily

Wiadomości Lekarskie · 30.04.2026 · (4) · 736-744

DOI: 10.36740/wlek/216191 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Wiadomości Lekarskie, online erschienen am 30.04.2026. Verfasst von Laith Rhabneh und 3 weiteren Autor:innen. Beteiligte Einrichtung: DEPARTMENT OF INTERNAL MEDICINE, HACKENSACK MERIDIAN HEALTH OCEAN UNIVERSITY MEDICAL CENTER, BRICK TOWNSHIP, UNITED STATES. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Antagonists, Cognitive Dysfunction, Heart Failure.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The purpose of this study was to compare 5-year cognitive outcomes in patients with HFrEF who receive angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). Material and methods Retrospective cohort study of: 1) 135,873 adults with HFrEF (International Classification of Diseases-10th Revision-Clinical Modification [ICD-10-CM] codes: I50.2 or I50.4) started on ACEI between Aug 1, 2019 and Aug 1, 2024; and 2) 135,873 propensity matched patients receiving ARBs during that time. Data were obtained from the TriNetX Research Network, encompassing 80 health care organizations in the United States. The primary endpoint was the composite of cognitive decline (ICD-10-CM: R41.8), dementia (ICD-10-CM: F01-F03), and Alzheimer’s disease (ICD-10- CM: G30).

Results

At 5 years,17,679 patients on ACEI met the primary endpoint vs 16,345 patients on ARBs (5-year incidence: 30.71% vs 28.54%; HR: 1.153; 95% CI: 129-1.178; P < 0.001), with consistently higher rates of cognitive decline (24.94% vs 22.81%; HR: 1.146; 95% CI: 1.119-1.174; P < 0.001), dementia (15.63% vs 13.71%; HR:1.204; 95% CI: 1.168-1.241; P < 0.001), and Alzheimer’s disease (4.15% vs 3.51%; HR: 1.202; 95% CI: 1.131-1.277; P < 0.001) in the ACEI cohort.

Conclusions

ACEI was associated with higher 5-year rates of neurocognitive disorders when compared to ARBs in patients with HFrEF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCognitive DysfunctionHeart FailureHumansRetrospective StudiesFemaleMaleAgedMiddle AgedDatabases, Factual

Stichwörter der Autor:innen

cognitive declinedementianeurocognitive disordersARBsHFrEFACEIs

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • DEPARTMENT OF INTERNAL MEDICINE, HACKENSACK MERIDIAN HEALTH OCEAN UNIVERSITY MEDICAL CENTER, BRICK TOWNSHIP, UNITED STATES.
  • DEPARTMENT OF INTERNAL MEDICINE, ASCENSION SAINT AGNES HOSPITAL, BRICK TOWNSHIP, UNITED STATES.
  • INTERNAL MEDICINE DEPARTMENT, UNIVERSITY OF MARYLAND MIDTOWN CAMPUS, BALTIMORE, UNITED STATES.

Zitieren

APA

Rhabneh, L., Ababneh, R., Al-Muhtaseb, A., & Aloqaily, M. (2026). Effects of Angiotensin Converting Enzyme Inhibitors versus Angiotensin Receptor Blockers on Cognitive Decline: A Retrospective Real-World Database Study. Wiadomości Lekarskie, 736-744. https://doi.org/10.36740/wlek/216191

Vancouver

Rhabneh L, Ababneh R, Al-Muhtaseb A, Aloqaily M. Effects of Angiotensin Converting Enzyme Inhibitors versus Angiotensin Receptor Blockers on Cognitive Decline: A Retrospective Real-World Database Study. Wiadomości Lekarskie. 2026:736-744. doi:10.36740/wlek/216191

BibTeX
@article{Rhabneh2026,
  author = {Rhabneh, Laith and Ababneh, Raed and Al-Muhtaseb, Abdallah and Aloqaily, Mohammed},
  title = {Effects of Angiotensin Converting Enzyme Inhibitors versus Angiotensin Receptor Blockers on Cognitive Decline: A Retrospective Real-World Database Study},
  journal = {Wiadomości Lekarskie},
  year = {2026},
  number = {4},
  pages = {736--744},
  doi = {10.36740/wlek/216191}
}
Kostenlos starten →